Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries. Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are available regarding pharmacokinetics and especially population pharmacokinetics.
Patients and methods: Thirty-one patients with advanced epithelial cancer classified as International Federation of Gynecology and Obstetrics stage IIIC were included in the study. Blood and IP samples were taken over a 24-hour period during and after IP treatment. Both total and ultrafiltered (Uf) platinum (Pt) concentrations were analysed using a population approach with nonlinear mixed-effects modelling (NONMEM®) software. Improvement of the model with covariates was performed as well as assessment of the model using bootstrap and posterior visual predictive methods.
Results: Both IP fluid and serum pharmacokinetics were satisfactorily described with a three-compartment model for both Uf Pt and total Pt concentrations. The covariates were bodyweight for the IP volume of the total Pt model. A nomogram, based on the results of the Monte Carlo simulations, displays a dose recommendation regarding both the risk of renal toxicity and the potent efficacy of the treatment. A limited sampling strategy (LSS) allowing the estimation of potential risk of renal toxicity is also described.
Conclusion: The pharmacokinetics of cisplatin during peroperative IP chemotherapy could be successfully fitted with the present model, which allowed a dosing strategy accompanied by an LSS to facilitate the follow-up of patients.
- Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration
Volume 48, Issue 3 , pp 169-180
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. UMR645, INSERM, Besançon, France
- 2. Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, CHU Besançon, Besançon, France
- 3. Groupe Hospitalier Cochin Saint-Vincent de Paul, U663, INSERM, Université Paris-Descartes, Service de Pharmacologie Clinique, Paris, France
- 4. Service d’Oncologie, Hôpital Jean Minjoz, Besançon, France
- 5. Service de Chirurgie Oncologique, Hôpital Jean Minjoz, Besançon, France
- 6. Centre Régional de Lutte contre le Cancer Leclerc, Dijon, France